Latest U.S. Recalls — FDA & NHTSA Records

Latest records

Latest recalls — page 79

The newest recall records with useful source details are listed here.

FoodApr 15, 2026

MEI YU CHENG DA TRADING Olive Skewers individually wrapped and packaged in clear recall — FDA H-0658-2026

Products contain banned sweetener: cyclamates.

Class IIIFDA: TerminatedMEI YU CHENG DA TRADING INC

FoodApr 15, 2026

Pure Vitamins and Natural Supplements Red Bull Extreme Male Enhancement Supplement, total of recall — FDA H-0655-2026

FDA analysis revealed the presence of undeclared sildenafil

Class IFDA: OngoingPure Vitamins and Natural Supplements, LLC

FoodApr 15, 2026

MEI YU CHENG DA TRADING DADI NONGFU DRIED SALT CHILLI VEGETABLE recall — FDA H-0657-2026

Products contain banned sweetener: cyclamates.

Class IIIFDA: TerminatedMEI YU CHENG DA TRADING INC

FoodApr 15, 2026

Pure Vitamins and Natural Supplements Blue Bull Extreme Male Enhancement Supplement, total recall — FDA H-0654-2026

FDA analysis revealed the presence of undeclared sildenafil

Class IFDA: OngoingPure Vitamins and Natural Supplements, LLC

FoodApr 15, 2026

Riverence Provisions net wt recall — FDA H-0662-2026

Label declares cream cheese but does not declare milk

Class IIFDA: OngoingRiverence Provisions LLC

FoodApr 15, 2026

Zarlengo Italian Ice Zarlengo's Chocolate Chocolate Chip Gelato packaged in recall — FDA H-0650-2026

Soy Lecithin listed in ingredients statement, but Soy is not mentioned in the contains statement.

Class IIFDA: TerminatedZarlengo Italian Ice

FoodApr 15, 2026

Zarlengo Italian Ice Zarlengo's Double Dark Chocolate Gelato packaged in 1 Gallon recall — FDA H-0652-2026

Soy Lecithin listed in ingredients statement, but Soy is not mentioned in the contains statement.

Class IIFDA: TerminatedZarlengo Italian Ice

DrugApr 15, 2026

Lanreotide Injection, 120 mg*/0.5 mL, Box contains 1 Pre-filled syringe and 1 safety needle recall — FDA D-0422-2026

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Class IIFDA: OngoingCipla USA, Inc.

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL), 1,000 recall — FDA D-0434-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

Fagron Compounding Services Vancomycin HCL, 1 gram added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0442-2026

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Class IIFDA: OngoingFagron Compounding Services

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 250 mL recall — FDA D-0431-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 50 mL x60, Becton, Dickson and Company recall — FDA D-0429-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP 0.9% (450 mg per 50 mL) (9 mg per mL) 50 recall — FDA D-0425-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 1,000 recall — FDA D-0433-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

DEXTROSE 5% Dextrose Injection, USP 5 g per 100 mL (50 mg per mL) 100 mL in a 100 mL recall — FDA D-0436-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

DEXTROSE 5% Dextrose Injection, USP 12.5 g per 250 mL (50 mg per mL) 250 mL in a 250 mL recall — FDA D-0437-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

Clonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0474-2026

CGMP Deviations: use of an unapproved raw material

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc

DrugApr 15, 2026

DEXTROSE 5% Dextrose Injection, USP 2.5 g per 50 mL (50 mg per mL) 50 mL in a 100 mL recall — FDA D-0435-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

Lanreotide Injection, 120 mg/0.5 mL, Box contains 1 Pre-filled syringe, Single dose only recall — FDA D-0423-2026

Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.

Class IIFDA: OngoingCipla USA, Inc.

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 900 mg per 100 mL (9 mg per mL) 100 mL recall — FDA D-0430-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

Fagron Compounding Services Vancomycin HCI, 1.25 grams added to 250 mL, 0.9% Sodium Chloride recall — FDA D-0440-2026

Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port

Class IIFDA: OngoingFagron Compounding Services

DrugApr 15, 2026

Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 recall — FDA D-0472-2026

CGMP Deviations: use of an unapproved raw material

Class IIFDA: OngoingTeva Pharmaceuticals USA, Inc

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, (4,500 mg per 500 mL) (9 mg per mL) 500 recall — FDA D-0428-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

DrugApr 15, 2026

SODIUM CHLORIDE 0.9% Sodium Chloride Injection, USP, 0.9% (900 mg per 100 mL) (9 mg per mL) recall — FDA D-0426-2026

Lack of Assurance of Sterility

Class IIFDA: OngoingFresenius Kabi USA, LLC

Browse by month

Recent recall archives

Browse recent months with enough recall history for useful comparison.

Full archive →